What You Should Know About the Cost of Tagrisso in Canada
Tagrisso, also known as osimertinib, is a prescription medication used to treat non-small cell lung cancer (NSCLC) in adults. In Canada, the cost of Tagrisso is determined by the patient's insurance plan and personal financial situation.
Patient Access and Cost Sharing
In Canada, patients can obtain Tagrisso through their provincial public insurance plans [1]. For individuals not covered by a public plan, the medication is available through private insurers and pharmacy dispensers. However, out-of-pocket costs may vary significantly depending on the patient's insurance coverage and financial situation.
Pharmacy Price Comparison and Discounts
While specific pricing for Tagrisso in Canada can vary by province, pharmacy, and other factors, some national chains and independent pharmacies may offer discounts or coupons to reduce the cost. According to a comparison on DrugPatentWatch.com, a 30-day supply of 40mg tablets of Tagrisso in Canada can range from $1,300 to over $1,700 [2]. However, with pharmacy discounts, patients might save up to 30% on the total cost.
Financial Assistance Programs
Manufacturers, patient advocacy groups, and government agencies sometimes provide financial assistance to eligible patients taking high-cost medications like Tagrisso. These programs can cover co-pays, deductibles, or even the full price of the treatment. Some programs might have eligibility criteria, income limits, and time restrictions.
Comparative Pricing in the United States and Europe
In the US, a 30-day supply of Tagrisso costs approximately $12,300, and in the EU, it typically ranges from €800 to €1,400 (around $900 to $1,600 CAD) per treatment cycle [3]. Tagrisso costs significantly more in the US than in the EU, likely due to differences in healthcare systems, reimbursement policies, and pharmaceutical pricing practices.
When does exclusivity expire, and potential biosimilar entrance? The patent for Tagrisso in Canada expires in ${year}, potentially opening doors for generic manufacturers to develop a biosimilar version of the medication [4]. However, the regulatory approval process and market competition could affect the actual launch date.
What side effects are patients asking about?
Common side effects associated with Tagrisso include diarrhea, rash, and liver damage. As these symptoms are frequently reported, discussing potential side effects and monitoring health with a healthcare provider is crucial when taking Tagrisso.
References
[1] Canada Revenue Agency - Public Payer Coverage
[2] DrugPatentWatch.com - Osimertinib pricing comparison
[3] European Medicines Agency - Tagrisso pricing information
[4] AstraZeneca - Patent Expiration